Ceccherini I, Romei C, Barone V, Pacini F, Martino E, Loviselli A, Pinchera A, Romeo G
Laboratorio di Genetica Molecolare, Istituto G. Gaslini, Genova, Italy.
J Endocrinol Invest. 1994 Mar;17(3):201-4. doi: 10.1007/BF03347719.
Following the recent identification of specific germline mutations of the RET proto-oncogene in Multiple Endocrine Neoplasia type 2A (MEN2A) patients, we looked for mutations of this gene in a pedigree showing recurrence of MEN2A and localized Cutaneous Lichen Amyloidosis (CLA). Basal calcitonin and/or pentagastrin test performed in all the 10 available members of this pedigree confirmed the clinical diagnosis and allowed the presymptomatic identification of an additional carrier. A cys634-->tyr missense mutation, already reported as causative in MEN2A patients, was identified after SSCP analysis and direct sequencing of exon 11 of the RET protooncogene in one individual affected with both MEN2A and CLA, thus suggesting a common etiology for the two disorders. Taking advantage of the observation of an RsaI restriction site in the sequence surrounding the mutated codon, we could demonstrate that the same mutation is present in three other affected members, in the presymptomatic carrier and in one additional 25 years old healthy member who shows a mildly positive pentagastrin test.
在最近发现2A型多发性内分泌腺瘤病(MEN2A)患者中RET原癌基因存在特定的种系突变后,我们在一个显示MEN2A复发和局限性皮肤苔藓样淀粉样变(CLA)的家系中寻找该基因的突变。对这个家系中所有10名可用成员进行的基础降钙素和/或五肽胃泌素试验证实了临床诊断,并允许对另外一名携带者进行症状前鉴定。在对一名同时患有MEN2A和CLA的个体进行RET原癌基因第11外显子的SSCP分析和直接测序后,发现了一个cys634→tyr错义突变,该突变已被报道为MEN2A患者的致病原因,因此提示这两种疾病有共同的病因。利用在突变密码子周围序列中观察到的RsaI限制性酶切位点,我们可以证明另外三名受影响成员、症状前携带者以及一名25岁的健康成员(其五肽胃泌素试验呈轻度阳性)中也存在相同的突变。